Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Accounts Payables (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Accounts Payables readings, the most recent being $418000.0 for Q4 2017.

  • On a quarterly basis, Accounts Payables rose 23.67% to $418000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $418000.0, a 23.67% increase, with the full-year FY2017 number at $418000.0, up 23.67% from a year prior.
  • Accounts Payables hit $418000.0 in Q4 2017 for Eledon Pharmaceuticals, up from $189000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.4 million in Q1 2015 to a low of $5000.0 in Q4 2013.
  • Median Accounts Payables over the past 5 years was $886000.0 (2016), compared with a mean of $1.2 million.
  • Biggest five-year swings in Accounts Payables: surged 15200.0% in 2014 and later plummeted 85.37% in 2017.
  • Eledon Pharmaceuticals' Accounts Payables stood at $5000.0 in 2013, then surged by 15200.0% to $765000.0 in 2014, then skyrocketed by 57.91% to $1.2 million in 2015, then tumbled by 72.02% to $338000.0 in 2016, then rose by 23.67% to $418000.0 in 2017.
  • The last three reported values for Accounts Payables were $418000.0 (Q4 2017), $189000.0 (Q3 2017), and $374000.0 (Q2 2017) per Business Quant data.